Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.
Almandoz JP, Miras AD, Blüher M, Orozco Del Pino P, Mojdami D, Batterham RL, Trice K, Goebel B, Tangi F
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.